<DOC>
	<DOCNO>NCT00891878</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether capecitabine effective give alone together sunitinib malate treat patient metastatic esophageal cancer gastroesophageal junction cancer . PURPOSE : This randomized phase II trial study well capecitabine work compare capecitabine give together sunitinib malate first-line therapy treat patient metastatic cancer esophagus gastroesophageal junction .</brief_summary>
	<brief_title>Capecitabine With Without Sunitinib Malate First-Line Therapy Treating Patients With Metastatic Cancer Esophagus Gastroesophageal Junction</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival elderly ( age ≥ 65 year ) and/or poor performance status patient metastatic adenocarcinoma esophagus gastroesophageal junction treat capecitabine verus without sunitinib malate . - Report indicator efficacy regimen , include confirm response rate , overall survival , time tumor progression , duration response , time treatment failure . - Compare adverse event profile regimens patient . Secondary - Explore whether certain key protein associate anti-VEGF therapy able predict tumor response . - Bank paraffin-embedded tissue block slide , blood product future study . OUTLINE : This multicenter study . Patients stratify accord gender ( male v female ) , ECOG performance status ( 0 vs 1 v 2 ) , age ( ≥ 65 year vs &lt; 65 year ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral capecitabine twice daily day 1-14 . Patients experience disease progression may crossover arm II physician 's discretion . - Arm II : Patients receive oral capecitabine arm 1 oral sunitinib malate daily day 1-21 . In arm , course repeat every 21 day absence disease progression unacceptable toxicity . Tumor tissue sample collect baseline evaluation protein marker possible predictor tumor response regimen . Samples analyze IHC expression level marker After completion study therapy , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma esophagus gastroesophageal junction Metastatic disease Unresectable disease curative option Measurable disease ≥ 1 lesion whose long diameter accurately measure ≥ 2.0 cm conventional technique ≥ 1.0 cm spiral CT Not candidate conventional multidrug chemotherapy regimen fairly standard dosing ( i.e. , patient able tolerate least 80 % standard dosing ) Patients offer decline conventional multidrug chemotherapy eligible No known CNS metastases PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 age ≥ 65 year OR PS 2 age ≥ 18 year &lt; 65 year Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Total bilirubin normal Alkaline phosphatase ≤ 2 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN Creatinine clearance ≥ 60mL/min AST ALT ≤ 2.5 time ULN ( ≤ 5 time ULN presence liver metastasis ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Willing provide tissue sample central review research purpose Able swallow pills No immunocompromised patient ( relate use corticosteroid ) , include patient know HIVpositive No comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate study interfere significantly proper assessment safety toxicity prescribe regimens No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement No NYHA class III IV heart failure No uncontrolled hypertension except discretion treat oncologist No active malignancy except nonmelanoma skin cancer carcinoma situ cervix No known dihydropyrimidine dehydrogenase deficiency ( DPD ) PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , immunotherapy , biological therapy recurrent metastatic cancer Prior chemotherapy radiotherapy allow administer adjuvant neoadjuvant therapy complete surgical resection original cancer achieve No prior sunitinib malate No prior radiotherapy &gt; 30 % marrow cavity time More 4 week since prior major surgery At least 12 day since prior concurrent CYP3A4 inducer , include rifampin , rifabutin , carbamazepine , phenobarbital , phenytoin , St. John 's wort , efavirenz , tipranavir At least 7 day since prior concurrent CYP3A4 inhibitor , include azole antifungal ( ketoconazole , itraconazole ) , clarithromycin , erythromycin , diltiazem , verapamil , HIV protease inhibitor ( indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) , delavirdine No concurrent specific treatment ( hormonal therapy ) patient history prior malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma gastroesophageal junction</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
</DOC>